Hercules Capital Receives a BBB+ Affirmed Investment Grade Corporate and Credit Rating from Kroll Bond Rating Agency, Inc.
HTGCSAN MATEO, Calif.--(BUSINESS WIRE)--Hercules Capital, Inc. (NYSE: HTGC) (“Hercules” or the “Company”), the largest and leading specialty financing provider to innovative venture, growth and established stage companies backed by some of the leading and top-tier venture capital and select private equity firms, today announced that Kroll Bond Rating Agency, Inc. (“KBRA”) has affirmed Hercules’ investment grade corporate and credit rating of BBB+. KBRA issued a statement announcing the affirmation
Hercules Capital Closes Upsized Institutional Notes Offering of $350.0 Million 6.000% Unsecured Notes due 2030
HTGCSAN MATEO, Calif.--(BUSINESS WIRE)--Hercules Capital, Inc. (NYSE: HTGC) (“Hercules” or the “Company”), today announced that it has closed an upsized underwritten public offering of $350.0 million in aggregate principal amount of 6.000% notes due June 2030 (the “Notes”). The Notes are unsecured and bear interest at a rate of 6.000% per year, payable semiannually, will mature on June 16, 2030 and may be redeemed in whole or in part at any time or from time to time at the Company’s option at par,
Hercules Capital Renews and Increases Its Credit Facility with MUFG Bank, Ltd. to $440.0 Million
HTGCSAN MATEO, Calif.--(BUSINESS WIRE)--Hercules Capital, Inc. (NYSE: HTGC) (“Hercules” or the “Company”), the largest and leading specialty finance provider to innovative venture, growth and established stage companies backed by some of the leading and top-tier venture capital and select private equity firms, today announced that it has upsized and renewed its existing $400.0 million credit facility with MUFG Bank, Ltd. (“MUFG”) with an upsized credit facility under which Goldman Sachs Bank USA, A
Hercules Capital Prices Upsized Institutional Notes Offering of $350.0 Million 6.000% Notes due 2030
HTGCSAN MATEO, Calif.--(BUSINESS WIRE)--Hercules Capital, Inc. (NYSE: HTGC) (“Hercules” or the “Company”), today announced that it has priced an upsized underwritten public offering of $350.0 million in aggregate principal amount of 6.000% notes due June 2030 (the “Notes”). The closing of the transaction is subject to customary closing conditions and the Notes are expected to be delivered and paid for on June 16, 2025. The Notes are unsecured and bear interest at a rate of 6.000% per year, payable
Merck's Dealmaking Intensifies With MoonLake Bid As Keytruda Patent Cliff Nears: Report
HTGCMerck reportedly offered over $3 billion for MoonLake Immunotherapeutics, targeting its late-stage inflammatory drug as it faces revenue pressure from Keytruda's looming patent cliff.
Hercules Capital Q1 EPS $0.45 Misses $0.47 Estimate, Sales $119.50M Miss $122.19M Estimate
HTGCWells Fargo Maintains Overweight on Hercules Capital, Lowers Price Target to $19
HTGCUBS Maintains Neutral on Hercules Capital, Lowers Price Target to $18
HTGCWhat Analysts Are Saying About Hercules Capital Stock
HTGCKeefe, Bruyette & Woods Maintains Outperform on Hercules Capital, Lowers Price Target to $20.5
HTGCPiper Sandler Maintains Overweight on Hercules Capital, Lowers Price Target to $20
HTGCMoonLake Enters Agreement With Hercules Capital For Up To $500M In Non-Dilutive Capital
HTGCSavara Enters Loan And Security Agreement With Hercules Capital For Up To $200M
HTGCCompass Point Maintains Neutral on Hercules Capital, Raises Price Target to $20
HTGCWhat 4 Analyst Ratings Have To Say About Hercules Capital
HTGCJMP Securities Reiterates Market Outperform on Hercules Capital, Maintains $22 Price Target
HTGCHercules Capital Q4 NII $0.49
HTGCPhathom Pharma Reports Revenue-Interest Financing For Up To $260M In Non-Dilutive Capital, Including Upfront Payment Of $100M In Cash, Added $160M In Payment Upon FDA Approval Of Vonoprazan
HTGC